Skip to main content
    V

    Vivos Therapeutics Inc (VVOS)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $0.08
    -0.02 (-16.12%)

    Market Cap: $3.29M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Vivos Therapeutics Inc (VVOS) Financials: Revenue, Profit and Cash Flow

    Updated Sep 30, 2026. Financial statements from company filings, amounts in US dollars.

    Vivos Therapeutics reported revenue of $17.44M for the fiscal year ended Dec 31, 2025, up 16.0% from the year before. That year, net income was -$21.23M with a net margin of -121.7%, operating cash flow was -$15.26M and free cash flow was -$22.79M. The quarter ended Sep 30, 2026 had revenue of $6.41M and net income of -$1.97M.

    Revenue and Margins

    Over the 7 years to Dec 2025, revenue grew from $3.79M, a compound annual rate of 24.4%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$17.44M+16.0%60.4%-114.1%-121.7%
    Dec 2024$15.03M+8.9%60.0%-74.3%-74.1%
    Dec 2023$13.80M-13.9%59.9%-125.3%-98.4%
    Dec 2022$16.02M-5.1%62.5%-156.2%-148.8%
    Dec 2021$16.89M-35.4%74.6%-120.7%-120.2%
    Dec 2020$26.13M+129.4%39.8%-46.1%-46.1%
    Dec 2019$11.39M+200.4%76.0%-92.8%-94.4%
    Dec 2018$3.79MN/A71.5%-219.8%-222.5%
    Annual, fiscal years ended Dec 2018 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Revenue$17.44M$15.03M$13.80M$16.02M$16.89M$26.13M$11.39M$3.79M
    Cost of revenue$6.90M$6.01M$5.53M$6.00M$4.28M$2.65M$2.74M$1.08M
    Gross profit$10.54M$9.02M$8.27M$10.02M$12.60M$10.41M$8.66M$2.71M
    Operating income-$19.89M-$11.17M-$17.30M-$25.03M-$20.38M-$12.04M-$10.58M-$8.34M
    Net income-$21.23M-$11.14M-$13.58M-$23.84M-$20.29M-$12.06M-$10.75M-$8.44M
    EBITDAN/A-$10.55M-$12.96M-$24.46M-$19.66M-$11.32M-$9.89M-$7.73M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$6.41M$5.15M$5.14M$3.82M$6.78M$3.82M$3.02M$3.70M$3.86M$4.05M$3.42M$3.25M
    Gross profit$3.31M$2.95M$3.06M$2.99M$3.94M$2.11M$1.51M$2.10M$2.33M$2.65M$1.94M$2.09M
    Operating income-$3.90M-$4.83M-$6.62M-$6.38M-$4.73M-$4.87M-$3.92M-$2.81M-$2.65M-$1.94M-$3.79M-$4.13M
    Net income-$1.97M-$5.52M-$7.75M-$6.95M-$5.40M-$5.01M-$3.86M-$2.83M-$2.62M-$1.93M-$3.76M-$4.26M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $8.82M exceeded cash and equivalents by $6.79M. Shareholder equity was negative, at -$1.49M, as total liabilities of $26.70M exceeded total assets of $25.15M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Total assets$25.15M$15.28M$10.73M$13.72M$33.69M$25.33M$7.55M$8.20M
    Current assets$4.38M$7.47M$2.46M$5.42M$27.32M$20.39M$1.98M$2.01M
    Cash and equivalents$2.03M$6.26M$1.64M$3.52M$24.03M$18.21M$469.35K$1.25M
    Total liabilities$26.70M$7.33M$10.32M$8.92M$8.15M$8.41M$9.18M$3.38M
    Short-term debt$8.35M$0$474.00K$419.00K$1.26M$867.00K$3.71M$161.54K
    Long-term debt$469.00K$0N/AN/AN/A$423.00K$0$525.00K
    Shareholder equity-$1.49M$7.95M$411.00K$4.80M$25.54M$16.92M-$2.94M$4.83M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$22.86M$24.14M$25.04M$25.15M$25.64M$26.03M$11.28M$15.28M$15.35M$15.84M$11.80M$10.73M
    Total liabilities$20.69M$28.13M$26.31M$26.70M$23.11M$21.45M$6.88M$7.33M$7.68M$9.49M$11.22M$10.32M
    Cash and equivalents$247.00K$1.77M$2.11M$2.03M$3.09M$4.40M$2.34M$6.26M$6.31M$6.90M$2.61M$1.64M
    Shareholder equity$2.36M-$3.81M-$1.14M-$1.49M$2.53M$4.58M$4.41M$7.95M$7.67M$6.35M$582.00K$411.00K
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow-$15.26M-$12.69M-$11.95M-$19.59M-$15.73M-$5.68M-$5.34M-$5.31M
    Capital expenditures$7.53M$568.00K$853.00K$924.00K$2.40M$120.00K$175.60K$1.25M
    Free cash flow-$22.79M-$13.26M-$12.80M-$20.51M-$18.13M-$5.80M-$5.52M-$6.56M
    Dividends paidN/AN/AN/AN/AN/A$3.72M$3.76MN/A
    Share repurchases$837.00K$1.36M$1.08M$0$2.24MN/A$159.89KN/A
    Investing cash flow-$7.53M-$568.00K-$853.00K-$924.00K-$2.61M-$120.00K$86.22K-$1.12M
    Financing cash flow$18.56M$17.88M$10.92M$0$24.17M$23.54M$4.47M$5.25M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$3.18M-$3.15M-$6.01M-$3.81M-$4.16M-$3.49M-$3.80M-$2.94M-$4.19M-$3.05M-$2.52M-$2.75M
    Capital expenditures$61.00K$416.00K$18.00K$6.72M$83.00K$771.00K$122.00K$165.00K$192.00K$60.00K$151.00K$165.00K
    Free cash flow-$3.24M-$3.56M-$6.03M-$10.53M-$4.24M-$4.26M-$3.92M-$3.10M-$4.38M-$3.11M-$2.67M-$2.91M
    Last 12 quarters

    Frequently Asked Questions About VVOS

    What is Vivos Therapeutics' annual revenue?

    Vivos Therapeutics reported revenue of $17.44M for the fiscal year ended Dec 31, 2025.

    How fast is Vivos Therapeutics' revenue growing?

    Revenue was up 16.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 2.9%.

    Is Vivos Therapeutics profitable?

    No. Vivos Therapeutics reported net income of -$21.23M for the fiscal year ended Dec 31, 2025, with a net margin of -121.7%.

    How much free cash flow does VVOS generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$15.26M minus capital expenditures of $7.53M produced free cash flow of -$22.79M.

    How much debt does Vivos Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $469.00K, short-term debt of $8.35M and cash and equivalents of $2.03M.